Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 3/2022

02.02.2022 | Original Article

Sexual dimorphism in the relation between sex hormones and osteoporosis in patients with type 2 diabetes mellitus

verfasst von: Cui Ran, Xu Xiaojuan, Gao Wenxue, Fei Zhaoliang, Sheng Hui, Qu Shen

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To investigate the association between sex hormones and osteoporosis in type 2 diabetic mellitus (T2DM) patients.

Materials and methods

We performed a retrospective study in patients with T2DM. The patients were assigned into three groups (normal bone mineral density, osteopenia, and osteoporosis) in both sexes. The clinical characteristics, bone metabolic markers, and sex hormones were compared. The relationship between the sex hormones and osteoporosis was analyzed by ordinary regression analysis. Statistical analysis was performed using SPSS 26.0.

Results

A total of 795 T2DM patients (446 men ≥ 50 years old and 349 postmenopausal women) were identified and analyzed. The osteoporosis group had the lowest estradiol level in men (P = 0.013) and the highest follicle-stimulating hormone (FSH) level in women (P = 0.042). In the multivariate analysis, men with lower estradiol levels (< 87.96 pmol/L) had a nearly 1.6-fold increased risk for osteoporosis than those with the higher estradiol levels (> 122.82 pmol/L). In addition, women with lower FSH (< 41.17 IU/L) had nearly 0.6-fold for osteoporosis compared to those with higher FSH (> 60.83 IU/L) after adjusting for age, duration of T2DM, body mass index, pulse pressure, creatinine clearance, glycosylated hemoglobin, fasting C-peptide, and estradiol (in FSH) or FSH (in estradiol).

Conclusion

In T2DM, the estrogen level was negatively correlated with osteoporosis in men, and the FSH level was positively correlated with the osteoporosis in women.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Almeida M, Laurent MR, Dubois V et al (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135–187CrossRef Almeida M, Laurent MR, Dubois V et al (2017) Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev 97:135–187CrossRef
2.
Zurück zum Zitat Parfitt AM, Mundy GR, Roodman GD et al (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150–159CrossRef Parfitt AM, Mundy GR, Roodman GD et al (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150–159CrossRef
3.
Zurück zum Zitat Stepan JJ, Hruskova H, Kverka M (2019) Update on menopausal hormone therapy for fracture prevention. Curr Osteoporos Rep 17:465–473CrossRef Stepan JJ, Hruskova H, Kverka M (2019) Update on menopausal hormone therapy for fracture prevention. Curr Osteoporos Rep 17:465–473CrossRef
4.
Zurück zum Zitat Greendale GA, Edelstein S, Barrett-Connor E (1997) Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 12:1833–1843CrossRef Greendale GA, Edelstein S, Barrett-Connor E (1997) Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 12:1833–1843CrossRef
5.
Zurück zum Zitat Araujo AB, Travison TG, Leder BZ et al (2008) Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 93:2135–2141CrossRef Araujo AB, Travison TG, Leder BZ et al (2008) Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men. J Clin Endocrinol Metab 93:2135–2141CrossRef
6.
Zurück zum Zitat Sowers MR, Greendale GA, Bondarenko I et al (2003) Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 14:191–197CrossRef Sowers MR, Greendale GA, Bondarenko I et al (2003) Endogenous hormones and bone turnover markers in pre- and perimenopausal women: SWAN. Osteoporos Int 14:191–197CrossRef
7.
Zurück zum Zitat Gallagher CM, Moonga BS, Kovach JS (2010) Cadmium, follicle-stimulating hormone, and effects on bone in women age 42–60 years, NHANES III. Environ Res 110:105–111CrossRef Gallagher CM, Moonga BS, Kovach JS (2010) Cadmium, follicle-stimulating hormone, and effects on bone in women age 42–60 years, NHANES III. Environ Res 110:105–111CrossRef
8.
Zurück zum Zitat García-Martín A, Reyes-García R, García-Castro JM et al (2012) Role of serum FSH measurement on bone resorption in postmenopausal women. Endocrine 41:302–308CrossRef García-Martín A, Reyes-García R, García-Castro JM et al (2012) Role of serum FSH measurement on bone resorption in postmenopausal women. Endocrine 41:302–308CrossRef
9.
Zurück zum Zitat Xu ZR, Wang AH, Wu XP et al (2009) Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women. Clin Chim Acta 400:8–13CrossRef Xu ZR, Wang AH, Wu XP et al (2009) Relationship of age-related concentrations of serum FSH and LH with bone mineral density, prevalence of osteoporosis in native Chinese women. Clin Chim Acta 400:8–13CrossRef
10.
Zurück zum Zitat Karvonen-Gutierrez CA, Park SK, Kim C (2016) Diabetes and menopause. Curr DiabRep 16:20 Karvonen-Gutierrez CA, Park SK, Kim C (2016) Diabetes and menopause. Curr DiabRep 16:20
11.
Zurück zum Zitat Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053CrossRef Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053CrossRef
12.
Zurück zum Zitat Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women’s health initiative hormone trial. Diabetologia 47:1175–1187CrossRef Margolis KL, Bonds DE, Rodabough RJ et al (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women’s health initiative hormone trial. Diabetologia 47:1175–1187CrossRef
13.
Zurück zum Zitat Kanaya AM, Herrington D, Vittinghoff E et al (2003) Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 138:1–9CrossRef Kanaya AM, Herrington D, Vittinghoff E et al (2003) Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 138:1–9CrossRef
14.
Zurück zum Zitat Dandona P, Bhatia V, Chaudhuri A et al (2007) Inverse relationship between FSH and CRP concentrations in post menopausal women with type 2 diabetes. Diabetes 56:A597 Dandona P, Bhatia V, Chaudhuri A et al (2007) Inverse relationship between FSH and CRP concentrations in post menopausal women with type 2 diabetes. Diabetes 56:A597
15.
Zurück zum Zitat Ching-Lung C, Kung AWC, Tan KCB (2018) Serum follicle stimulating hormone is associated with reduced risk of diabetes in postmenopausal women: The Hong Kong Osteoporosis Study. Maturitas 114:41–45CrossRef Ching-Lung C, Kung AWC, Tan KCB (2018) Serum follicle stimulating hormone is associated with reduced risk of diabetes in postmenopausal women: The Hong Kong Osteoporosis Study. Maturitas 114:41–45CrossRef
16.
Zurück zum Zitat Bertone-Johnson ER, Virtanen JK, Niskanen L et al (2017) Association of follicle-stimulating hormone levels and risk of type 2 diabetes in older postmenopausal women. Menopause 24:796–802CrossRef Bertone-Johnson ER, Virtanen JK, Niskanen L et al (2017) Association of follicle-stimulating hormone levels and risk of type 2 diabetes in older postmenopausal women. Menopause 24:796–802CrossRef
17.
Zurück zum Zitat American Diabetes Association (2014) Standards of medical care in diabetes 2014. Diabetes Care 37:S14–S80CrossRef American Diabetes Association (2014) Standards of medical care in diabetes 2014. Diabetes Care 37:S14–S80CrossRef
18.
Zurück zum Zitat American Diabetes Association (2019) 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 42:S13–S28CrossRef American Diabetes Association (2019) 2 Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care 42:S13–S28CrossRef
19.
Zurück zum Zitat Xu X, Zhang M, Fei Z, Sheng H, Qu S, Cui R (2021) Calcification of lower extremity arteries is related to the presence of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a cross-sectional observational study. Osteoporos Int 32:1185–1193CrossRef Xu X, Zhang M, Fei Z, Sheng H, Qu S, Cui R (2021) Calcification of lower extremity arteries is related to the presence of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a cross-sectional observational study. Osteoporos Int 32:1185–1193CrossRef
20.
Zurück zum Zitat Cosman F, Beur SJD, Leboff MS et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381CrossRef Cosman F, Beur SJD, Leboff MS et al (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381CrossRef
21.
Zurück zum Zitat Jeyabalan J, Viollet B, Smitham P et al (2013) The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 24:2659–2670CrossRef Jeyabalan J, Viollet B, Smitham P et al (2013) The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 24:2659–2670CrossRef
22.
Zurück zum Zitat Furat Rencber S, Kurnaz Ozbek S, Eraldemır C et al (2018) Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res 11:55CrossRef Furat Rencber S, Kurnaz Ozbek S, Eraldemır C et al (2018) Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res 11:55CrossRef
23.
Zurück zum Zitat Hayakawa N, Suzuki A (2012) Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture. Clin Calcium 22:1383–1390PubMed Hayakawa N, Suzuki A (2012) Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture. Clin Calcium 22:1383–1390PubMed
24.
Zurück zum Zitat Nuche-Berenguer B, Moreno P, Esbrit P et al (2009) Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 84:453–461CrossRef Nuche-Berenguer B, Moreno P, Esbrit P et al (2009) Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcif Tissue Int 84:453–461CrossRef
25.
Zurück zum Zitat Richard JE, Anderberg RH, López-Ferreras L et al (2016) Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biol Sex Differ 16:6CrossRef Richard JE, Anderberg RH, López-Ferreras L et al (2016) Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biol Sex Differ 16:6CrossRef
26.
Zurück zum Zitat Seto-Young D, Paliou M, Schlosser J et al (2005) Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90:6099–6105CrossRef Seto-Young D, Paliou M, Schlosser J et al (2005) Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab 90:6099–6105CrossRef
27.
Zurück zum Zitat Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179–192CrossRef Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179–192CrossRef
28.
Zurück zum Zitat Hughes DE, Dai A, Tiffee JC et al (1996) estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2:1132–1136CrossRef Hughes DE, Dai A, Tiffee JC et al (1996) estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2:1132–1136CrossRef
29.
Zurück zum Zitat Almeida M, Iyer S, Martin-Millan M et al (2013) Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Investig 123:394–404CrossRef Almeida M, Iyer S, Martin-Millan M et al (2013) Estrogen receptor-alpha signaling in osteoblast progenitors stimulates cortical bone accrual. J Clin Investig 123:394–404CrossRef
30.
Zurück zum Zitat Almeida M, Han L, Martin-Millan M et al (2007) Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285–27297CrossRef Almeida M, Han L, Martin-Millan M et al (2007) Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282:27285–27297CrossRef
31.
Zurück zum Zitat Wu XY, Wu XP, Xie H et al (2010) Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women. Osteoporos Int 21:275–285CrossRef Wu XY, Wu XP, Xie H et al (2010) Age-related changes in biochemical markers of bone turnover and gonadotropin levels and their relationship among Chinese adult women. Osteoporos Int 21:275–285CrossRef
32.
Zurück zum Zitat Wang J, Zhang W, Yu C et al (2015) Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PLoS ONE 10:e0134986CrossRef Wang J, Zhang W, Yu C et al (2015) Follicle-stimulating hormone increases the risk of postmenopausal osteoporosis by stimulating osteoclast differentiation. PLoS ONE 10:e0134986CrossRef
33.
Zurück zum Zitat Khosla S, Melton LJ 3rd, Riggs BL (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26:441–451CrossRef Khosla S, Melton LJ 3rd, Riggs BL (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26:441–451CrossRef
34.
Zurück zum Zitat Finkelstein JS, Lee H, Leder BZ et al (2016) Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Investig 126:1114–1125CrossRef Finkelstein JS, Lee H, Leder BZ et al (2016) Gonadal steroid-dependent effects on bone turnover and bone mineral density in men. J Clin Investig 126:1114–1125CrossRef
35.
Zurück zum Zitat Sun L, Peng Y, Sharrow AC et al (2006) FSH directly regulates bone mass. Cell 125:247–260CrossRef Sun L, Peng Y, Sharrow AC et al (2006) FSH directly regulates bone mass. Cell 125:247–260CrossRef
36.
Zurück zum Zitat Mohsin S, Baniyas MM, Aldarmaki RS et al (2019) An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther 19:937–948CrossRef Mohsin S, Baniyas MM, Aldarmaki RS et al (2019) An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther 19:937–948CrossRef
37.
Zurück zum Zitat Lieben L, Callewaert F, Bouillon R (2009) Bone and metabolism: a complex crosstalk. Horm Res 71:134–138PubMed Lieben L, Callewaert F, Bouillon R (2009) Bone and metabolism: a complex crosstalk. Horm Res 71:134–138PubMed
Metadaten
Titel
Sexual dimorphism in the relation between sex hormones and osteoporosis in patients with type 2 diabetes mellitus
verfasst von
Cui Ran
Xu Xiaojuan
Gao Wenxue
Fei Zhaoliang
Sheng Hui
Qu Shen
Publikationsdatum
02.02.2022
Verlag
Springer Nature Singapore
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 3/2022
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-021-01291-6

Weitere Artikel der Ausgabe 3/2022

Journal of Bone and Mineral Metabolism 3/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.